# US 2026/0308625 A1 · Compositions and methods for treating gjb2-related hearing loss

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0308625 A1
- Document ID: US20260308625A1
- Status: Published application
- Kind: A1
- Application number: 19/484,939
- Filed: 2024-05-17
- Published: 2026-10-08
- Earliest claimed: 2023-05-18
- Assignees: Decibel Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.
- Applicants: Decibel Therapeutics, Inc.; Regeneron Pharmaceuticals, Inc.
- Inventors: Joseph BURNS; Kathryn ELLIS; Tyler GIBSON; Kevin LEBO; Aayushi MANCHANDA; Gabriela PREGERNIG; Leah SABIN; Meghan DRUMMOND SAMUELSON
- Web page: https://patentgrep.com/patent/US20260308625A1

## CPC

- C12N 15/86: Viral vectors
- A61P 27/16: Otologicals
- C07K 14/47: from mammals
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure provides polynucleotides and nucleic acid vectors containing a gap junction protein beta 2 (GJB2) regulatory construct operably linked to a polynucleotide encoding a Gjb2 protein (e.g., a wild-type human Gjb2 protein). These polynucleotides and vectors can be used to express Gjb2 in GJB2-expressing cells, including cochlear supporting cells, and can, thus, be used for the treatment of subjects having or at risk of developing GJB2-related hearing loss.

## Claims

### Claim 1

A nucleic acid vector comprising, in 5′-to-3′ order:
(a) a GJB2 regulatory construct having a sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, and a sequence having at least 90% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2, operably linked to:
(b) a human GJB2 coding sequence selected from the group consisting of SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 28, a sequence having at least 90% sequence identity to SEQ ID NO: 3 and comprising at least 50% fewer CG dinucleotides than wild-type GJB2, and a sequence having at least 90% sequence identity to SEQ ID NO: 4 or SEQ ID NO: 28, operably linked to:
(c) a polyadenylation (polyA) signal sequence.

### Claim 2 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 3.

### Claim 3 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 4.

### Claim 4 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 1 and the human GJB2 coding sequence has the sequence of SEQ ID NO: 28.

### Claim 5 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 3.

### Claim 6 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 4.

### Claim 7 (depends on 1)

The nucleic acid vector of claim 1, wherein the GJB2 regulatory construct has the sequence of SEQ ID NO: 2; and the human GJB2 coding sequence has the sequence of SEQ ID NO: 28.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The nucleic acid vector of any one of claims 1-7, wherein the polyA signal sequence has at least 90% sequence identity to SEQ ID NO: 6 or SEQ ID NO: 7.

### Claim 9 (depends on 8)

The nucleic acid vector of claim 8, wherein the polyA signal sequence has the sequence of SEQ ID NO: 6.

### Claim 10 (depends on 8)

The nucleic acid vector of claim 8, wherein the polyA signal sequence has the sequence of SEQ ID NO: 7.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The nucleic acid vector of any one of claims 1-10, wherein the vector comprises a stop codon positioned at the 3′ end of the GJB2 coding sequence.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The nucleic acid vector of any one of claims 1-11, wherein the vector further comprises a first polynucleotide having at least 90% sequence identity to SEQ ID NO: 8 that comprises a first member of an ITR pair and is positioned 5′ of the GJB2 regulatory construct sequence and a second polynucleotide having at least 90% sequence identity to SEQ ID NO: 9 that comprises a second member of an ITR pair and is positioned 3′ of the polyA signal sequence.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The nucleic acid vector of any one of claims 1-11, wherein the vector further comprises a first polynucleotide having at least 90% sequence identity to SEQ ID NO: 10 that comprises a first member of an ITR pair and is positioned 5′ of the GJB2 regulatory construct sequence and a second polynucleotide having at least 90% sequence identity to SEQ ID NO: 11 that comprises a second member of an ITR pair and is positioned 3′ of the polyA signal sequence.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The nucleic acid vector of any one of claims 1-13, wherein the nucleic acid vector is a viral vector.

### Claim 15 (depends on 14)

The nucleic acid vector of claim 14, wherein the viral vector is an adeno-associated virus (AAV) vector.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

A composition comprising the nucleic acid vector of any one of claims 1-15; and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

A method of treating a subject having or at risk of developing GJB2-related hearing loss, comprising administering to an inner ear of the subject a therapeutically effective amount of the nucleic acid vector of any one of claims 1-15 or the composition of claim 16.

### Claim 18 (depends on 17)

The method of claim 17, wherein the GJB2-related hearing loss is DFNB1 or DFNA3.

### Claim 19 (depends on 18)

The method of claim 18, wherein the subject has a mutation in GJB2, a mutation in GJB6, or a mutation in both GJB2 and GJB6.
